I-18 Bojana Golubovic Population pharmacokinetics of sirolimus in adult kidney transplant patients Wednesday 10:20-11:50 |
I-21 Mario Gonzalez Sales Population pharmacokinetic analysis of tesamorelin in HIV-infected patients and healthy volunteers. Wednesday 10:20-11:50 |
I-27 Chihiro Hasegawa Modeling & simulation of ONO-5334, a cathepsin K inhibitor, to support dose selection in osteoporosis Wednesday 10:20-11:50 |
I-42 Niclas Jonsson A Population PK Analysis of Nebivolol and Valsartan in Combination Therapy Wednesday 10:20-11:50 |
I-48 Takayuki Katsube Population PK/PD Modeling of Lusutrombopag, Thrombopoietin Receptor Agonist, in Healthy Volunteers for Exploring PK/PD Covariates Wednesday 10:20-11:50 |
I-53 Yo Han Kim Early characterization of ticagrelor using modeling and simulation analysis of the in vitro platelet aggregation test and human pharmacokinetic data Wednesday 10:20-11:50 |
I-59 Ryuji Kubota Population Pharmacokinetics of Ospemifene and Evaluation for Exposure Increase Wednesday 10:20-11:50 |
II-01 Brigitte Lacroix Modeling the anti-drug antibody response in rheumatoid arthritis patients treated with certolizumab pegol Wednesday 15:10-16:30 |
II-07 Kha Le Population PKPD Modeling of Geographic Atrophy Disease Progression, Target Mediated Disposition and Treatment Effect of Lampalizumab Wednesday 15:10-16:30 |
II-12 Yan Li PK/PD Modeling of Tumor Growth Inhibition in Xenograft Mice to Optimize Experimental Design and Improve Study Efficiency Wednesday 15:10-16:30 |
II-15 Jos Lommerse PKPD model of erythropoietin and hemoglobin response in rats following administration of prolyl hydroxylase inhibitors Wednesday 15:10-16:30 |
II-18 Mats Magnusson A Population PK/PD Analysis of Nebivolol and Valsartan Combination Therapy Wednesday 15:10-16:30 |
II-23 Matilde Merino-Sanjuán Simulation of Plasmatic Taurine Levels In Well And Undernourished Rats After Enteral Diet Administration. Wednesday 15:10-16:30 |
II-25 Enrica Mezzalana A Target-Mediated Drug Disposition model to quantify the relationship between Otelixizumab in vitro concentration and TCR/CD3 engagement Wednesday 15:10-16:30 |
II-26 Raymond Miller Modelling and simulation of the activity of intrinsic Factor Xa following edoxaban treatment Wednesday 15:10-16:30 |
II-28 Dirk Jan Moes Population pharmacokinetics and pharmacogenetics of once daily tacrolimus formulation in liver transplant patients Wednesday 15:10-16:30 |
II-44 Sung Min Park Population pharmacokinetics and CYP3A5 genotype effect of S-amlodipine in healthy Korean male subjects Wednesday 15:10-16:30 |
II-47 Nathalie Perdaems Translational PKPD modeling of a cardiovascular drug and the interrelationship between blood pressure and heart rate in animals and human Wednesday 15:10-16:30 |
II-49 Philippe Pierrillas Preclinical evaluation of the dose-concentration-marker-tumor growth relationship of a new pro-apoptotic compound using population PK-PD modeling Wednesday 15:10-16:30 |
II-58 Hyerang Roh Characterization of Nocturia Patient's Urination Pattern and Assessment of Drug Treatment Using Joint Ordered Categorical Model Wednesday 15:10-16:30 |
III-06 Franc Andreu Solduga Pharmacokinetic modeling of enterohepatic circulation of mycophenolic acid in renal transplant patients. Thursday 10:05-11:30 |
III-10 Ioanna Athanasiadou Hyperhydration may alter urine pharmacokinetic profile of drugs: A simulation study using budesonide as model drug Thursday 10:05-11:30 |
III-14 Jan Berkhout Mechanism-based approaches to the analysis of comparative effectiveness in osteoporosis Thursday 10:05-11:30 |
III-23 Karl Brendel Population Pharmacokinetic modelling for a molecule S and its glucuronide metabolite including enterohepatic recycling Thursday 10:05-11:30 |
III-30 Ana Catalan-Latorre A Mechanistic Population Pharmacokinetic Model For Taurine In Well And Undernourished Rats Thursday 10:05-11:30 |
III-45 Emmanuelle Comets Population pharmacokinetics of mycophenolate acid and its metabolite in liver transplant patients Thursday 10:05-11:30 |
III-54 Paul Matthias Diderichsen Dose selection of GLPG0634, a selective JAK1 inhibitor, for rheumatoid arthritis Phase 2B studies: PK/PD modeling of pSTAT1 biomarker and DAS28 clinical response Thursday 10:05-11:30 |
IV-04 Andre Schäftlein Population modeling of the relationship between the pharmacokinetics of the oral thrombin inhibitor dabigatran etexilate and coagulation biomarkers in patients with non-valvular atrial fibrillation from the RE-LY trial Thursday 15:15-16:40 |
IV-14 Mijeong Son Population Pharmacokinetic-Pharmacodynamic modeling of Olemsartan in Healthy Korean Volunteers Thursday 15:15-16:40 |
IV-17 Elisabet Størset Evaluation of dosing strategies to achieve targeted tacrolimus exposure after adult kidney transplantation Thursday 15:15-16:40 |
IV-32 Pavan Vajjah Exposure-response relationship of certolizumab pegol in psoriatic arthritis patients and comparison of ACR 20/50/70 response rates in the two dosage regimens Thursday 15:15-16:40 |
IV-45 Franziska Weber Evaluation of candidate drugs to induce the redundant gene ABCD2 as an alternative treatment option for X-linked adrenoleukodystrophy Thursday 15:15-16:40 |
IV-48 Pawel Wiczling PK/PD of propofol and fentanyl in patients undergoing abdominal aortic surgery - the influence of cardiac output and drug interactions Thursday 15:15-16:40 |